Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Aging is a major risk factor for many chronic diseases. This study aimed to examine the effects of antihypertensive, lipid-lowering, and antidiabetic drugs on biological aging. We included 672 participants and 2746 repeated measurements from the Swedish Adoption/Twin Study of Aging. Self-reported medicine uses were categorized into antidiabetic, antihypertensive, and lipid-lowering drugs. A total of 12 biomarkers for biological aging (BA biomarkers) were included as outcomes. Conditional generalized estimating equations were applied conditioning on individuals to estimate the drug effect on BA biomarker level within the same person when using or not using the drug. Chronological age, body mass index, smoking status, number of multiple medication uses, blood pressure, blood glucose level, and apoB/apoA ratio were adjusted for as covariates in the model. Overall, using antihypertensive drugs was associated with a decrease in one DNA-methylation age (PCGrimAge: beta = − 0.39, 95%CI = − 0.67 to − 0.12). When looking into drug subcategories, calcium channel blockers (CCBs) were associated with a decrease in several DNA-methylation ages (PCHorvathAge beta = − 1.28, 95%CI = − 2.34 to − 0.21; PCSkin&bloodAge beta = − 1.34, 95%CI = − 2.61 to − 0.07; PCPhenoAge beta = − 1.74, 95%CI = − 2.58 to − 0.89; PCGrimAge beta = − 0.57, 95%CI = − 0.96 to − 0.17) and in functional biological ages (functional age index beta = − 2.18, 95%CI = − 3.65 to − 0.71; frailty index beta = − 1.31, 95%CI = − 2.43 to − 0.18). However, the results within other drug subcategories were inconsistent. Calcium channel blockers may decrease biological aging captured by the BA biomarkers measured at epigenetic and functional level. Future studies are warranted to confirm these effects and understand the underlying biological mechanisms.
Cited Times [WOS]:0
|Document Type||Journal Article|
|Department||School of Public Health and Emergency Management|
1.Department of Medical Epidemiology and Biostatistics,Karolinska Institutet,Stockholm,171 77,Sweden
2.School of Public Health and Emergency Management,Southern University of Science and Technology,Shenzhen,China
3.Department of Clinical Sciences,Danderyd Hospital,Karolinska Institutet,Solna,Sweden
4.Brain Aging and Behavior Section,National Institute on Aging,Baltimore,United States
5.Longitudinal Studies Section,National Institute on Aging,Baltimore,United States
6.Department of Psychology,University of California,Riverside,United States
7.Aging Research Network-Jönköping (ARN-J),School of Health and Welfare,Jönköping University,Jönköping,Sweden
8.Center for Economic and Social Research,University of Southern California,Los Angeles,United States
9.Faculty of Social Sciences (Health Sciences) and Gerontology Research Center (GEREC),University of Tampere,Tampere,Finland
Tang，Bowen,Li，Xia,Wang，Yunzhang,et al. Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging[J]. GeroScience,2023.
Tang，Bowen.,Li，Xia.,Wang，Yunzhang.,Sjölander，Arvid.,Johnell，Kristina.,...&Hägg，Sara.(2023).Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging.GeroScience.
Tang，Bowen,et al."Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging".GeroScience (2023).
|Files in This Item:||There are no files associated with this item.|
|Recommend this item|
|Export to Endnote|
|Export to Excel|
|Export to Csv|
|Similar articles in Google Scholar|
|Similar articles in Baidu Scholar|
|Similar articles in Bing Scholar|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.